Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OQL011 for VEGFR inhibitor-associated hand-foot skin reaction
CTR20221809Phase 2Active
- Sponsor
- Ankura Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitroglycerin in Hand-foot skin reaction (HFSR) (4 arms), sponsored by Ankura Therapeutics. Primary endpoint: Proportion of patients achieving IGA-HFSR grade 0 or 1. Started Jan 2023; status: active.
02
Drugs
nitroglycerin
03
Conditions
Hand-foot skin reaction (HFSR)
Beyond the preview
Go deeper on CTR20221809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221809.